Compare Alcon AG (ALC) vs Microsoft (MSFT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Microsoft — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Microsoft trades at $383.01 (market cap $2.89T). The key difference: Microsoft is far larger — about 88.4× Alcon AG's market cap, and Microsoft pays the higher dividend (0.94%). Which is the better fit depends on your goals.
| ALC | MSFT | |
|---|---|---|
Market Cap | $32.69B | $2.89T |
Sector | Health | Technology |
52-Week High | $92.22 | $542.07 |
52-Week Low | $62.02 | $352.83 |
Enterprise Value | $36.28B | $2.87T |
Dividend Yield | 0.54% | 0.94% |
Volume | — | 36,654,621 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Microsoft (MSFT) trades at $383.08, down 0.95% on the day, with a bullish technical signal despite recent weakness. The company shows robust fundamentals with revenue growth to $281.72B in 2025 and net income of $101.83B, supported by strong cash flow from operations of $136.16B. Analysts maintain an 80.49% buy rating with a consensus price target of $550.43, reflecting confidence in its AI and cloud initiatives.
Outlook remains positive driven by AI leadership and Azure momentum, though risks include elevated capital expenditure concerns and competitive pressures. The stock offers long-term growth potential but faces near-term volatility from market sentiment and spending scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
